Invex Health Private Limited

Invex Health Private Limited is a privately held pharmaceutical company established on December 19, 2018, in Neemuch, Madhya Pradesh, India. The company is registered under the Corporate Identification Number (CIN) U24290MP2018PTC047309 and is classified as a private non-government company. Initially known as Invax Healthcare Private Limited, the company rebranded to Invex Health Private Limited to better reflect its strategic focus. The registered office is located at 84 Jawahar Nagar, Neemuch, Madhya Pradesh, 458441, India.

The authorized and paid-up capital of Invex Health Private Limited is ₹5.00 million each, indicating a modest financial base. The company operates in the pharmaceutical sector, specializing in the development and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of July 2025, Invex Health Private Limited employed between 11 to 50 individuals, reflecting its status as a small to medium-sized enterprise. The company's official website is www.invexhealth.com, providing information about its products, services, and contact details.

Invex Health Private Limited operates manufacturing facilities in Neemuch, Madhya Pradesh, and Mumbai, Maharashtra. The Neemuch facility serves as the registered office, while the Mumbai facility is situated at Office No. 105, 1st Floor, The Summit Business Bay-Omkar, Andheri East, Mumbai – 400093. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed. However, the company's focus on finished pharmaceutical formulations suggests that these facilities are equipped to handle the production of various dosage forms, including tablets, capsules, syrups, and injections.

The leadership team of Invex Health Private Limited comprises two directors:

• Anudesh Goyal: Serving as a director since the company's inception on December 19, 2018.

• Neha Agrawal: Also a director since December 19, 2018.

Detailed information regarding other key executives, such as the CEO, CFO, and other senior management personnel, is not publicly available. The company's leadership appears to be relatively small, which is common in privately held companies of this size.

Invex Health Private Limited's export activities, as reported by TransData Nexus, indicate a total export value of $300,000 USD across six shipments, with products spanning one therapeutic category. The top two exported products are Melphalan and Rituximab, each contributing $150,000 USD to the total export value. Both products are classified under the Advanced Oncology therapeutic category, highlighting the company's focus on oncology treatments. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed. This lack of publicly available information suggests that Invex Health Private Limited may not have established a significant presence in these regulated markets.

Invex Health Private Limited has established distributor partnerships across more than 25 countries, including the USA, Canada, UAE, Southeast Asia, and India. This global reach indicates the company's strategic focus on emerging markets. While the company emphasizes its commitment to providing quality and affordable products in these regions, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available. The absence of such information suggests that Invex Health Private Limited may not have pursued WHO prequalification or similar certifications for its products.

Invex Health Private Limited's export data reveals a total export value of $300,000 USD across six shipments, with products spanning one therapeutic category. The top two exported products are Melphalan and Rituximab, each contributing $150,000 USD to the total export value. Both products are classified under the Advanced Oncology therapeutic category, highlighting the company's focus on oncology treatments. This concentration on a single therapeutic area suggests a strategic emphasis on oncology, potentially leveraging specialized expertise and resources. However, the limited diversification in product offerings may expose the company to risks associated with market fluctuations and regulatory changes specific to the oncology sector.

Specific details regarding Invex Health Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The absence of such information suggests that the company may not have pursued FDA approvals for its products, potentially limiting its market access in the United States. This lack of FDA approvals could impact the company's ability to market and sell its products in the U.S. market, which is known for its stringent regulatory requirements.

Invex Health Private Limited's website highlights its focus on in-licensing and out-licensing innovative products, as well as its participation in global tenders. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The absence of such certifications suggests that the company may not have pursued these international quality standards, which are often essential for market access in various regions.

Invex Health Private Limited is registered with the Ministry of Corporate Affairs (MCA) under the Corporate Identification Number (CIN) U24290MP2018PTC047309. The company's registered office is located at 84 Jawahar Nagar, Neemuch, Madhya Pradesh, 458441, India. Specific details regarding the company's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly available. The absence of such information suggests that Invex Health Private Limited may not have pursued these regulatory approvals, potentially limiting its ability to manufacture and export pharmaceutical products within India and to international markets.

As of March 28, 2026, there are no publicly available records indicating that Invex Health Private Limited has received any Form 483 observations, warning letters, or import alerts from regulatory bodies such as the FDA, EMA, or CDSCO. The absence of such records suggests that the company has not faced significant regulatory actions or compliance issues in the public domain. However, the lack of publicly available information regarding the company's regulatory approvals and certifications may limit the ability to fully assess its compliance status.

Invex Health Private Limited operates in the competitive pharmaceutical industry, focusing on the oncology segment with products like Melphalan and Rituximab. While specific market share data is not publicly available, the company's export data indicates a concentration on a limited number of products within a single therapeutic category. This strategic focus may position Invex Health Private Limited to compete effectively in niche markets. However, the limited diversification in product offerings could expose the company to competitive pressures from larger, more diversified pharmaceutical companies operating in the oncology space.

Invex Health Private Limited emphasizes its focus on in-licensing and out-licensing innovative products, as well as its participation in global tenders. The company's product portfolio spans various therapy areas, including pharmaceuticals, nutraceuticals, and medical devices. This breadth of offerings may provide a competitive advantage in catering to diverse market needs. However, the company's limited publicly available information regarding regulatory approvals and certifications may pose challenges in establishing credibility and trust with potential partners and customers.

Invex Health Private Limited's strategic direction appears to focus on in-licensing and out-licensing innovative products, as well as participating in global tenders. The company's product portfolio spans various therapy areas, including pharmaceuticals, nutraceuticals, and medical devices. This diversified approach may enable the company to adapt to changing market dynamics and explore new growth opportunities. However, the lack of publicly available information regarding regulatory approvals and certifications may limit the company's ability to fully capitalize on these strategic initiatives.

Invex Health Private Limited's export data indicates a total export value of $300,000 USD across six shipments, with products spanning one therapeutic category. The